Disruption of Spike Priming in Virus Entry: Tetrandrine as a Pan-Coronavirus Inhibitor

Abstract

The emergence of novel and highly transmissible coronavirus (CoVs) highlights the urgent need for broad-spectrum antiviral agents. In our pursuit of effective treatments for coronavirus, we identified tetrandrine, the traditional Chinese medicine, as a pan-coronavirus inhibitor, exhibiting efficacy against HCoV-229E, HCoV-OC43, SARS-CoV-2, and its major variants of concern (VOCs), including alpha, beta, and omicron. Mechanistic investigations revealed that tetrandrine primarily targets the viral entry stage by binding to the Spike protein, disrupting its interaction with the host protease transmembrane serine protease 2 (TMPRSS2), and promoting Spike protein degradation, ultimately blocking the membrane fusion. Drug resistance selection study identified two mutations, G688R and D814Y, at S2 subunit of Spike, which reduced HCoV-229E's sensitivity to tetrandrine, supporting its direct action on the viral fusion machinery. Molecular docking and molecular dynamic (MD) simulation together with co-IP assay also verified the disruption of Spike-TMPRSS2 complex formation by tetrandrine. Importantly, tetrandrine treatment reduced viral load and mitigated neuropathological damage in infected neonatal mice. These findings establish tetrandrine as a broad-spectrum coronavirus entry inhibitor and offer mechanistic insights into its antiviral activity, providing a promising candidate for therapeutic development against current and future coronavirus threats.

Keywords

coronavirus / entry / Spike / tetrandrine / transmembrane serine protease 2

References

[1] E. J. Snijder and M. C. Horzinek, “Toroviruses: Replication, Evolution and Comparison With Other Members of the Coronavirus-Like Superfamily,” Journal of General Virology 74, no. 11 (1993): 2305-2316.

[2] D. X. Liu, J. Q. Liang, and T. S. Fung, “Human Coronavirus-229E,-OC43,-NL63, and-HKU1 (Coronaviridae),” Encyclopedia of Virology (2021): 428-440.

[3] Y. Yan, L. Chang, and L. Wang, “Laboratory Testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): Current Status, Challenges, and Countermeasures,” Reviews in Medical Virology 30, no. 3 (2020): e2106.

[4] D. R. Owen, C. M. Allerton, A. S. Anderson, et al., “An Oral SARS-CoV-2 Mpro Inhibitor Clinical Candidate for the Treatment of COVID-19,” Science 374, no. 6575 (2021): 1586-1593.

[5] J. Hammond, H. Leister-Tebbe, A. Gardner, et al., “Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults With Covid-19,” New England Journal of Medicine 386, no. 15 (2022): 1397-1408.

[6] W. Fischer, J. J. Eron, W. Holman, et al., “Molnupiravir, an Oral Antiviral Treatment for COVID-19,” MedRxiv (2021). https://doi.org/10.1101/2021.06.17.21258639.

[7] A. Jayk Bernal, M. M. Gomes da Silva, D. B. Musungaie, et al., “Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients,” New England Journal of Medicine 386, no. 6 (2022): 509-520.

[8] T. Kovacs, K. Kurtan, Z. Varga, P. Nagy, G. Panyi, and F. Zakany, “Veklury®(remdesivir) Formulations Inhibit Initial Membrane-Coupled Events of SARS-CoV-2 Infection Due to Their Sulfobutylether-β-cyclodextrin Content,” British Journal of Pharmacology 180, no. 16 (2023): 2064-2084.

[9] J.-L. Zhang, Y.-H. Li, L.-L. Wang, et al., “Azvudine Is a Thymus-Homing Anti-SARS-CoV-2 Drug Effective in Treating COVID-19 Patients,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 414.

[10] C. B. Jackson, M. Farzan, B. Chen, and H. Choe, “Mechanisms of SARS-CoV-2 Entry Into Cells,” Nature Reviews Molecular Cell Biology 23, no. 1 (2022): 3-20.

[11] P. V'kovski, A. Kratzel, S. Steiner, H. Stalder, and V. Thiel, “Coronavirus Biology and Replication: Implications for SARS-CoV-2,” Nature Reviews Microbiology 19, no. 3 (2021): 155-170.

[12] M. J. Vincent, E. Bergeron, S. Benjannet, et al., “Chloroquine Is a Potent Inhibitor of SARS Coronavirus Infection and Spread,” Virology Journal 2, no. 1 (2005): 1-10.

[13] J. Liu, R. Cao, M. Xu, et al., “Hydroxychloroquine, a Less Toxic Derivative of Chloroquine, Is Effective in Inhibiting SARS-CoV-2 Infection in Vitro,” Cell Discovery 6, no. 1 (2020): 16.

[14] M. Hoffmann, H. Kleine-Weber, S. Schroeder, et al., “SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor,” Cell 181, no. 2 (2020): 271-280.e8.

[15] M. Hoffmann, S. Schroeder, H. Kleine-Weber, M. A. Müller, C. Drosten, and S. Pöhlmann, “Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19,” Antimicrobial Agents and Chemotherapy 64, no. 6 (2020): e00754-20.

[16] X. Wang, R. Cao, H. Zhang, et al., “The Anti-influenza Virus Drug, Arbidol Is an Efficient Inhibitor of SARS-CoV-2 in Vitro,” Cell Discovery 6, no. 1 (2020): 28.

[17] Z.-R. Zhang, Y.-N. Zhang, H.-Q. Zhang, et al., “Berbamine Hydrochloride Potently Inhibits SARS-CoV-2 Infection by Blocking S Protein-Mediated Membrane Fusion,” PLoS Neglected Tropical Diseases 16, no. 4 (2022): e0010363.

[18] D. Yi, Q. Li, H. Wang, et al., “Repurposing of Berbamine Hydrochloride to Inhibit Ebola Virus by Targeting Viral Glycoprotein,” Acta Pharmaceutica Sinica B 12, no. 12 (2022): 4378-4389.

[19] Y.-H. Jin, J. S. Min, S. Jeon, et al., “Lycorine, a Non-Nucleoside RNA Dependent RNA Polymerase Inhibitor, as Potential Treatment for Emerging Coronavirus Infections,” Phytomedicine 86 (2021): 153440.

[20] J. Chrzanowski, A. Chrzanowska, and W. Graboń, “Glycyrrhizin: An Old Weapon Against a Novel Coronavirus,” Phytotherapy Research 35, no. 2 (2021): 629-636.

[21] Y. Jiang, M. Liu, H. Liu, and S. Liu, “A Critical Review: Traditional Uses, Phytochemistry, Pharmacology and Toxicology of Stephania tetrandra S. Moore (Fen Fang Ji),” Phytochemistry Reviews 19 (2020): 449-489.

[22] S. Hu, J. Dutt, T. Zhao, and C. S. Foster, “Tetrandrine Potently Inhibits Herpes Simplex Virus Type-1-induced Keratitis in BALB/c Mice,” Ocular Immunology and Inflammation 5, no. 3 (1997): 173-180.

[23] J.-T. Liou, Z.-Y. Chen, L.-J. Ho, et al., “Differential Effects of Triptolide and Tetrandrine on Activation of COX-2, NF-κB, and AP-1 and Virus Production in Dengue Virus-Infected Human Lung Cells,” European Journal of Pharmacology 589, no. 1-3 (2008): 288-298.

[24] Y. Sakurai, A. A. Kolokoltsov, C.-C. Chen, et al., “Two-Pore Channels Control Ebola Virus Host Cell Entry and Are Drug Targets for Disease Treatment,” Science 347, no. 6225 (2015): 995-998.

[25] G. S. Gunaratne, Y. Yang, F. Li, T. F. Walseth, and J. S. Marchant, “NAADP-Dependent Ca²⁺ Signaling Regulates Middle East respiratory Syndrome-Coronavirus Pseudovirus Translocation Through the Endolysosomal System,” Cell Calcium 75 (2018): 30-41.

[26] Z.-R. Zhang, Y.-N. Zhang, X.-D. Li, et al., “A Cell-Based Large-Scale Screening of Natural Compounds for Inhibitors of SARS-CoV-2,” Signal Transduction and Targeted Therapy 5, no. 1 (2020): 218.

[27] P. M. Heister and R. N. Poston, “Pharmacological Hypothesis: TPC2 Antagonist Tetrandrine as a Potential Therapeutic Agent for COVID-19,” Pharmacology Research & Perspectives 8, no. 5 (2020): e00653.

[28] A. Khadilkar, Z. L. Bunch, J. Wagoner, et al., “Modulation of in Vitro SARS-CoV-2 Infection by Stephania tetrandra and Its Alkaloid Constituents,” Journal of Natural Products 86, no. 4 (2023): 1061-1073.

[29] J. Liu, F. Wang, X. Wang, et al., “Antiviral Effects and Tissue Exposure of Tetrandrine Against SARS-CoV-2 Infection and COVID-19,” MedComm 4, no. 1 (2023): e206.

[30] S. Zahmatkesh, M. Sillanpaa, Y. Rezakhani, and C. Wang, “Review of Concerned SARS-CoV-2 Variants Like Alpha (B. 1.1. 7), Beta (B. 1.351), Gamma (P. 1), Delta (B. 1.617. 2), and Omicron (B. 1.1. 529), as Well as Novel Methods for Reducing and Inactivating SARS-CoV-2 Mutants in Wastewater Treatment Facilities,” Journal of Hazardous Materials Advances 7 (2022): 100140.

[31] J. P. Evans and S.-L. Liu, “Role of Host Factors in SARS-CoV-2 Entry,” Journal of Biological Chemistry 297, no. 1 (2021): 100847.

[32] M. J. Roy, S. Winkler, S. J. Hughes, et al., “SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate,” ACS Chemical Biology 14, no. 3 (2019): 361-368.

[33] K. Shirato, K. Kanou, M. Kawase, and S. Matsuyama, “Clinical Isolates of Human Coronavirus 229E Bypass the Endosome for Cell Entry,” Journal of Virology 91, no. 1 (2017): e01387-16.

[34] X. Song, Y. Shi, W. Ding, et al., “Cryo-EM Analysis of the HCoV-229E Spike Glycoprotein Reveals Dynamic Prefusion Conformational Changes,” Nature Communications 12, no. 1 (2021): 141.

[35] L. Xing, Z. Liu, X. Wang, et al., “Early Fusion Intermediate of ACE2-Using Coronavirus Spike Acting as an Antiviral Target,” Cell 188, no. 5 (2025): 1297-1314.

[36] S. J. Dobson, J. Mankouri, and A. Whitehouse, “Identification of Potassium and Calcium Channel Inhibitors as Modulators of Polyomavirus Endosomal Trafficking,” Antiviral Research 179 (2020): 104819.

[37] B. Qian, Y. Hu, C. Liu, et al., “Tetrandrine (TET) Inhibits African Swine Fever Virus Entry Into Cells by Blocking the PI3K/Akt Pathway,” Virus Research 339 (2024): 199258.

[38] M. Shah, R. Yamin, I. Ahmad, et al., “In-Silico Evaluation of Natural Alkaloids Against the Main Protease and Spike Glycoprotein as Potential Therapeutic Agents for SARS-CoV-2,” PLoS ONE 19, no. 1 (2024): e0294769.

[39] B. Kolita, D. Borah, P. Hazarika, E. Phukan, and R. R. Borah, “Plant-Derived Antiviral Compounds as Potential COVID-19 Drug Candidates: In-Silico Investigation in Search of SARS-CoV-2 Inhibitors,” Trends in Sciences 20, no. 9 (2023): 5529.

[40] T. A. Tummino, V. V. Rezelj, B. Fischer, et al., “Drug-Induced Phospholipidosis Confounds Drug Repurposing for SARS-CoV-2,” Science 373, no. 6554 (2021): 541-547.

[41] B. Breiden and K. Sandhoff, “Emerging Mechanisms of Drug-Induced Phospholipidosis,” Biological Chemistry 401, no. 1 (2020): 31-46.

[42] H. Yan, J. Sun, K. Wang, et al., “Repurposing Carrimycin as an Antiviral Agent Against human Coronaviruses, Including the Currently Pandemic SARS-CoV-2,” Acta Pharmaceutica Sinica B 11, no. 9 (2021): 2850-2858.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.